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Summary Twenty patients receiving a variety of emetogenic cytotoxics (including cisplatin in 5) were given a
single i.v. infusion of 40,ugkg- 1 of BRL43694 (as the hydrochloride salt) in successive groups of 3-4 patients
between 0-6 hours after chemotherapy. Eleven patients were completely protected from vomiting; 9 had mild
to moderate nausea and vomiting, but none severe enough to require alternative anti-emetic 'rescue'. In 4 of
the patients in whom BRL43694 was delayed until 4-6h after chemotherapy, vomiting had already begun; in
each case immediate termination of vomiting occurred when BRL43694 was infused. No adverse effects
attributable to the anti-emetic were observed. Mean pharmacokinetic parameters in 14 patients in whom
plasma assay data are available were: Maximum observed concentration=30.7ngml-1; terminal phase half-
life =8.96h; total body clearance =0.376 (lh-1) kg- 1; apparent volume of distribution =2.851kg-1. This study
shows BRL43694 to be an effective and well tolerated anti-emetic. Further studies aimed at defining an
optimal dose and schedule for use against the most emetogenic cytotoxics are in progress.
Nausea and vomiting remain major problems in cancer
chemotherapy despite recent advances, such as the use of
high dose metoclopramide. One major disadvantage of high
dose metoclopramide is the relatively high incidence of extra-
pyramidal side effects in young patients. Even with optimum
use of established agents control of emesis is poor in a
proportion of patients, especially following administration of
cisplatin chemotherapy.
There is increasing evidence that the anti-emetic effect of
high dose metoclopramide is mediated by 5-
hydroxytryptamine antagonism at the 5HT-3 receptor
(Costall et al., 1986. Fozard & Mobarok, 1978. Miner &
Sanger, 1986). The recent synthesis of specific 5HT-3 recep-
tor antagonists (Richardson et al., 1985) has led to the
demonstration in animal models (Miner & Sanger, 1986) and
in man (Cunningham et al., 1987; Leibungut & Lancranjan,
1987) of the importance of 5HT-3 receptor antagonism in
anti-emesis.
BRL43694 [Endo-N-(9-methyl-9-azabicyclo-(3,3, I)-non-3-
yl)-I-methyl-indazole-3-carboxamide] has been recently
developed by Beecham Pharmaceuticals Research Division as
a selective 5HT-3 antagonist. In common with other agents
of this class it rapidly abolishes vomiting induced by cispla-
tin in ferrets (Boyle et al., 1987). In animals and in human
volunteer studies BRL43694 appears to have a significant
advantage over metoclopramide in that it lacks extra-
pyramidal and neuroleptic side effects.
The assessment of safety and tolerance to intravenous
doses in the range 2.5 to 3004ugkg-1 has been completed in
healthy volunteers. The compound was well tolerated at all
dosages with no effect on haematology or clinical chemistry
parameters, ECG, pulse, blood pressure or plasma prolactin
and aldosterone levels.
The major aims in this pilot study were to assess anti-emetic
efficacy against a variety of cytotoxic agents, and to assess
patient tolerance of BRL43694. It is not known whether
antagonism of 5HT-3 receptors should be attempted im-
mediately following chemotherapy, or several hours later
when vomiting generally starts. Thus one additional aim of
this study was to assess the importance of the time interval
between chemotherapy administration and treatment with
BRL43694.
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Patients and methods
Twenty patients (9 female, 11 males) with a mean age of
49.8 years took part in this open study. Seventeen patients
were chemotherapy naive, 3 had received prior chemo-
therapy in 1983-84. None of the patients had anticipatory
vomiting. Patients ages, diagnoses and chemotherapy
regimes are shown in Table I.
Patients with serious concurrent illness, myocardial infarc-
tion within the previous 6 months, cardiac arrythmias or
conduction disturbance, and those with significant hepatic
(>2 times normal range of bilirubin or transaminases) or
renal (creatinine> 1504umol 1 -1) dysfunction were excluded
from the study. All patients gave written informed consent
and the study protocol was approved by our local Ethical
Committee.
Successive groups of 4-6 patients were given BRL43694 at
a dose of 40,igkg-1 as a single i.v. infusion over 30min at
0, 2, 4 or 6h after completion of their first course of
chemotherapy. In all subsequent courses they were treated
with standard anti-emetics (usually a combination of nabi-
lone and prochlorperazine). Provision was made in the
protocol for alternative anti-emetic 'rescue' of patients who
did not respond to BRL43694.
Patients completed visual analogue scales (VAS) of
nausea, drowsiness and anxiety at 4-hourly intervals over
24h. Nausea, vomiting and adverse effects were also assessed
4-hourly by trained observers. In view of the CVS effects in
animals of high doses of BRL43694, the first 6 patients on
this study were electrocardiographically monitored for
30min following the infusion of BRL43694. All patients had
24h ambulatory ECG performed. All patients also had
hourly pulse and blood pressure measurements for 8 hours
following BRL43694 administration.
Blood samples were obtained before commencing the
infusion of BRL43694 and at the following times thereafter
for pharmacokinetic analyses:
0,1,2,3,4,5,6,7,8,24h.
The samples were taken into EDTA tubes and the plasma
separated by centrifugation, then frozen at -20°C and
stored to await assay using a specific HPLC technique
(Clarkson et al., 1988).
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Table I Patient characteristics
Diagnosis
breast
breast
teratoma
sarcoma
SCLC
teratoma
oesophageal
breast
ovary
lymphoma
breast
ovary
ovary
ACUP
SCLC
ACUP
lymphoma
myeloma
lung
teratoma
Chemotherapy regimen (and dose in mg m 2)
epirubicin 50
cyclophosphamide600 +5-FU600 +methotrexate50
cisplatinum5o +bleomycin15 +vincristinel .4
adriamycin75
adriamycin4o +cyclophosphamide750 +vincristine1.4 +VP -16 75
cisplatinum20 +bleomycin15 +VP-16 120
cisplatinum 100
epirubicin 100
carboplatin 400
cyclophosphamide600 +vincristine1.4
cyclophosphamide600 + 5-FU600 +methotrexate5O
carboplatin 400
carboplatin 400
adriamycin5O +cyclophosphamide600 + 5-FU 600
adriamycin 40+cyclophosphamide750 +vincristinel .4 +VP-16 75
cyclophosphamide 500 +adriamycin 50
adriamycin5O +cyclophosphamideSOO +vincristine1.4
adriamycin30 +cyclophosphamide100 +vincristineO.67
cisplatinum 100 +vindesine 3
cisplatinum50 +bleomycin15 +vincristine1.4
SCLC=small cell lung carcinoma; ACUP=adenocarcinoma of unknown primary site.
Results
Efficacy of BRL43694
The results of this part of the study are shown in Table II.
Overall 7 patients experienced neither nausea nor vomiting.
In 4 patients despite a lack of nausea noted on VAS, mild
nausea was reported to the observer. In the remaining 9
patients mild to moderate nausea occurred. Nine patients
vomited or had episodes of dry retching (mean number of
episodes=2.3; maximum =4). This was usually observed
more than 8-12h following the single infusion of BRL43694.
No patient required alternative anti-emetic 'rescue'.
Fourteen patients expressed a preference for BRL43694
over standard anti-emetics given with their second course of
chemotherapy; one patient preferred standard anti-emetics, 4
had no preference and one patient was not evaluable because
of a change in chemotherapy between courses one and two.
There was no clear advantage of delaying administration of
BRL43694 for 2, 4 or 6h rather than administration imme-
diately following chemotherapy.
Table II Efficacy of BRL43694
Interval between
chemotherapy and Nausea
No. BRL43694(h) rating
1 0 mild
2 0 mild
3 0 moderate
4 2 none
5 0 mild
6 2 mild
7 4 moderate
8 4 moderate
9 4 none
10 4 none
11 6 mild
12 6 none
13 4 none
14 6 mild
15 6 moderate
16 6 mild
17 2 mild
18 0 none
19 6 mild
20 4 none
Vomitl
retches
2
3
0
0
0
4
2
1
0
0
0
0
0
3
2
0
2
0
2
0
NE =non-evaluable patient because of
between course one and two; aPost BRL
tion' patients.
Time of onset Patient
(after chemo) preference
6 BRL
8 BRL
12 BRL
- BRL
8 none
9 NE
16 BRL8
12 BRL
BRL
- none
24 BRLa
- BRL
- BRL
6 BRL
9 none
8 BRLa
16 BRL
- none
6 other
BRLa
change in chemotherapy
assessments on 'interven-
In 4 of the patients in whom administration of BRL43694
was delayed until 4-6h after chemotherapy, vomiting had
already began to occur: in each case termination of vomiting
occurred as soon as BRL43694 was administered.
Tolerance of BRL43694
Mild sedation was noted in 6 cases, though because of
concomitant use of analgesics and night sedation the rela-
tionship to BRL43694 was unclear. No changes attributable
to the anti-emetic therapy was noted in routine haematologi-
cal or biochemical tests, acute cardiac monitoring, 24h ECG
records, blood pressure or pulse monitoring. No significant
changes occurred in the self-rating VAS of drowsiness of
anxiety.
Pharmacokinetics of BRL43694
Complete data are available for 14 patients in this study.
The area under the plasma concentration-time curve was
calculated using the log trapezoidal rule, from time 0 to the
last measured time point and then extrapolated from the last
time point to infinity. The terminal slope (Ke) was calculated
by regression analysis using the least squares method. The
terminal half life (Ti) was then calculated as 0.693/Ke. Total
body clearance was calculated as dose/AUC. The apparent
volume of distribution was calculated as total body
clearance/Ke. The individual results are shown in Table III.
Maximum observed plasma concentrations ranged from
14.5 to 48.3ngml-1, with a mean of 30.7ngml- 1. They
coincided with the end of the infusion in all but two
patients, where the highest concentration was seen in the
next sample. These Cmax values are comparable to those
noted in healthy volunteers at this dose level; 24.5 to
43.Ongml-1 (Zussman et al., 1988).
The terminal phase half-lives ranged from 1.5 to 13.3h in
13 patients, but was much longer (28.7h) in patient 10
though there was no obvious clinical indication of possible
problems in drug disposition in this patient. The mean
terminal half-life is 9h in these 14 patients. This is longer
than was seen in 10 healthy subjects receiving BRL43694 at
30-40 ygkg-1 (4.0h) although the range was also broad (2.5
to 7.1 h) in those individuals (Zussman et al., 1988).
Although elimination parameters are well defined in these
patients, they are based on a less intensive sampling schedule
than in healthy volunteers.
The wide range in half-lives of our patients resulted
mainly from variability in clearance values rather than in
apparent volumes of distribution. Mean clearance values are
Patient
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Age
59
40
31
62
49
18
54
43
60
73
61
57
49
55
33
41
62
60
63
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Table III Individual model-independent pharmacokinetic para-
meters in 14 patients
Parameter (units)
Cmax AUC CL Vd
No. (ngml-1) T2(h) (ng.hml ) ((1h-')kg1) (lkg1)
1 26.2 9.16 176.4 0.227 3.02
2 38.7 5.63 119.7 0.334 2.71
3 29.0 1.50 53.95 0.741 1.60
4 48.3 11.7 160.2 0.250 4.22
5 14.5 3.94 38.49 1.039 5.92
7 24.1 5.59 67.26 0.595 4.79
10 27.6 28.7 837.4 0.048 1.98
11 29.5 4.20 98.42 0.406 2.46
12 36.0 12.2 545.4 0.073 1.30
13 22.6 11.6 235.8 0.170 2.85
14 16.6 2.78 45.22 0.885 3.55
15 42.1 4.39 139.7 0.286 1.81
16 34.5 13.3 310.5 0.129 2.47
20 39.8 10.8 500.6 0.080 1.25
Mean 30.7 8.96 237.8 0.376 2.85
(CV%) 32 77 99 85 48
Cmax=maximum observed plasma concentration; T4=terminal
phase half-life; AUC=area under plasma concentration versus time
curve from zero to infinity; Cl=total body clearance, calculated as
dose/AUC; Vd=apparent volume of distribution, calculated as the
ratio of total body clearance to terminal phase rate constant.
lower in these patients than in healthy volunteers (0.376 and
0.480 (1 h-1)kg-' respectively).
In conclusion, the disposition of BRL43694 in this group
of patients may be different to that in healthy volunteers,
with a tendency towards longer half-lives due to reductions
in clearance. Despite this, however, maximum BRL43694
concentrations achieved are comparable with those in
healthy volunteers.
Discussion
This study shows BRL43694 to be an effective and very well
tolerated anti-emetic at an intravenous dose of 40,ugkg-1.
Our patients were receiving a variety of cytotoxics, some
more emetogenic than others, and it is worth noting that
only one of the five patients receiving cisplatin was com-
pletely protected by the single dose of BRL43694, although
all had some amelioration of nausea and vomiting (in
comparison to course two). However, from consideration of
the animal toxicology and volunteer studies, it is evident that
there is scope for dose escalation and scheduling changes of
BRL43694 which may result in even better control of
cisplatin induced emesis.
Such nausea and vomiting as were observed tended to
start more than 8-12 hours post BRL43694 (see Table II).
This might suggest that there is some threshold plasma level
below which anti-emetic efficacy is compromised. This would
suggest that multiple dosing may be appropriate. We could
not find a definite relationship between the time of anti-
emetic administration with respect to chemotherapy, and the
subsequent anti-emetic efficacy of BRL43694. It is probable
that any such relationship would require a larger patient
group to become evident.
There was no clear correlation between anti-emetic effi-
cacy and either peak plasma concentration of BRL43694 or
the area under the plasma concentration time curves for
individual patients in this study.
BRL43694 was well tolerated at this dosage, in particular
we did not observe any dysphoria, extra-pyramidal effects or
the degree of sedation noted with anti-emetics such as
metoclopramide or the cannabinoids. This is encouraging in
that it suggests there is a possibility of co-administration of
BRL43694 with established anti-emetics in the future, if the
5HT-3 receptor blockers are found not to be totally protec-
tive in their own right.
A remarkable finding in this study was the ability of
BRL43694 to immediately terminate established vomiting in
the 4 patients treated in this way. This effect mimics that
seen in pre-clinical studies of cisplatin induced vomiting in
ferrets (Boyle et al., 1987). Previous attempts to treat
patients in this way have involved aggressive multi-drug
regimens and have met with variable success; together with
increased risk of adverse effects or drug interaction with the
cytotoxics used (Piezia et al., 1984).
The observed differences in BRL43694 disposition between
patients and volunteers are interesting, though such differ-
ences are common in patients with malignancies. Nonethe-
less, the maximum concentrations achieved in both groups
are comparable.
These results are similar to those published for other 5HT-
3 antagonists (Cunningham et al., 1987; Leibungut &
Lancranjan, 1987) and confirm the anti-emetic potential for
this class of drugs. Currently further studies are underway to
define optimum dosage schedules, and it is hoped that a
repeated dose (6-hourly) regime based on the pharmacokine-
tic profile of BRL43694 may enhance the effect, particularly
against the most emetogenic cytotoxic agents.
We acknowledge the technical assistance of A. Clarkson and Dr S.
Thompson.
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